Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Patients with no prior chemotherapy who meet either of the listed below:

• Patient with stage IIIB or IV disease

• Patients with recurrent disease following potentially curative surgical resection

• Patients with previous chemotherapy up to one regimen

Exclusion Criteria:

• Patients with serious, uncontrolled medical illness

• Patients with previous therapy with taxanes